-
EOFlow Initiates Eco-Friendly Disposal Campaign for EOPatch in Korea Embracing and Integrating Environmental, Social, and Governance (ESG)
▶EOFlow will collect, process, and dispose of used EOPatch pumps in an environmentally safe manner ▶EOFlow will set up an Incentive Program for this Campaign EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, announced today that the Company is initiating an environmentally friendly disposal campaign to minimize the impact of used EOPatch pumps on the environment. As there are no environmental regulations or guidelines for proper disposal of used medical devices in Korea, used patc...Nov. 09. 2021 -
EOFlow to Raise 100 Billion Korean Won and Offer Stock Split Capital Raised Will Be Used For Global Market Expansion
▶ 100 billion Won to be raised with new common stock offering, to be followed by a 2:1 stock split EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that the Company will raise some 100 billion Won with new common stock offering, after which it will do a 2:1 stock split. The Company will make a new public offering of its common stocks. The company will issue up to 3,000,000 shares of common stocks, representing 25.99% of the current total number of issued shares. The...Oct. 28. 2021 -
EOFlow and Sinocare Establish a Joint Venture Company
▶ Sinocare is China’s Largest Diabetes Management Instrument Manufacturer ▶ Joint venture company to launch a full-scale effort for clinical study to obtain regulatory approval for EOPatch manufacturing and distribution in China ▶ High growth expected from EOPatch business in China where world’s largest diabetes population live EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that the Company will establish a joint venture company “SINOFLOW Co., Ltd...Oct. 27. 2021 -
EOFlow Begins Clinical Study of its Wearable Insulin Pump “EOPatch” on People With Type 2 diabetes in Korea
▶ This clinical study involves ten leading university hospitals and up to one hundred and thirty-six people with Type 2 diabetes. It is Korea’s largest ever clinical study employing insulin pumps. ▶ This pioneering study aims to demonstrate and validate efficacy of EOPatch for Type 2 diabetes therapy. EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that the Company completed enrollment of first patient in a clinical study on type 2 diabetes for its wearable in...Oct. 14. 2021 -
EOFlow Completes its First Shipment to Europe
▶ EOFlow’s European exclusive distributing partner Menarini to showcase the EOPatch at EASD 2021 EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has made its first shipment to Europe today. After launching the wearable insulin pump in Korea this March and obtaining the CE certification in May, EOFlow is now expanding its reach to Europe, starting with the first shipment completed on September 30. EOFlow officially launched its EOPatch, Korea’s first (and the w...Sep. 30. 2021 -
EOFLOW exhibits at 2016 KIMES
EOFLOW has exhibited its EOPatch wearable disposable insulin pump products at the 2016 Korea International Medical & Hospital Equipment Show (KIMES). Many potential business partners and end users visited our booth, with a significant number of Type-1 diabetic patients adding their names to the growing list of clinical trial volunteers.Mar. 21. 2016 -
EOFLOW moves in to a new campus
Eoflow has moved to a new location in Healthcare Innovation Park (HIP) run by Seoul National University Bundang Hospital (SNUH), located in Bundang, Korea. The new building is located in a 45,000m^2 campus situated at the foot of a green hill and boasts more than 78,000m^2 of office space. HIP promises to be a major healthcare innovation hub in Korea that nurtures synergistic business opportunities by facilitating cooperation among medical facilities, universities and healthcare companies large and small. HIP is not just a phy...Mar. 21. 2016 -
EOFLOW members appear in a major newspaper
EOFLOW and seven others were asked to pose for an article of a major newspaper covering the successes of TIPS, an important angel investment and incubation program initiated by the Korean government. Read the article in Korean at the newspaper website: http://news.joins.com/article/19699337Mar. 10. 2016 -
EOFLOW announces the funding closure
EOFLOW announces that it just closed its latest round of funding. ‘With this round, we have secured enough funds to complete the product development work and regulatory approvals of our EOPatch insulin delivery product,’ says the company.Oct. 06. 2015 -
EOFLOW exhibits at EASD 2015, Stockholm
EOFLOW exhibits a functional EOPatch wearable disposable insulin delivery product sample at the 51st EASD (European Association for the Study of Diabetes) Annual Meeting held in Stockholm, Sweden, 9/14-18. This is the first time ever that a functional EOPatch is displayed at a public event. Unlike in the previous events, EOFLOW has its own booth.Sep. 01. 2015 -
EOFLOW exhibits at ADA 2015, Boston
EOFLOW exhibits the latest prototype of EOPatch wearable disposable insulin delivery product sample at a business partner’s booth at the 75th Scientific Sessions of ADA (American Diabetes Association) held in Boston, MA, 06/05-09. This is the first time that EOPatch is introduced in a public event in the US.Jun. 01. 2015 -
EOFLOW is covered in an article
Venture Square, an online webzine that covers Korean start-up companies, runs an article on EOFLOW. To read the Korean article, click the link below: http://www.venturesquare.net/583394Apr. 30. 2015 -
EOFLOW awarded a government grant
EOFLOW is awarded a government R&D grant for developing a wearable drug delivery solution.Apr. 05. 2015 -
EOFLOW relocates to a new facility
EOFLOW relocates to a new facility in the City of Seongnam, a southern suburb of Seoul which hosts more technology start-up companies than any other place in Korea.Feb. 23. 2015 -
EOFLOW exhibits at EASD 2014, Vienna
EOFLOW introduces its conceptual prototype of EOPatch wearable disposable insulin delivery product at a business partner’s booth at the 50th EASD (European Association for the Study of Diabetes) Annual Meeting held in Vienna, Austria on 9/15-19. This is the first time ever that EOPatch is displayed at a public event outside of Korea.Sep. 01. 2014
Healthcare Innovation Park #H2202 Dolma-ro 172 Bundang-gu Seongnam-si Gyeonggi-do Republic of Korea
T (+82) 031-738-0200
F (+82) 031-738-0208
COPYRIGHT ⓒ 2017 EOFLOW CO., LTD. All Rights Reserved.
